# Capricor Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2023

- Company: [Capricor Therapeutics, Inc.](/companies/capr.md) (CIK 1133869)
- Form: 10-Q
- Filed: 2023-08-08
- Accepted by EDGAR: Aug 8, 2023, 08:01 ET
- Period: 2023-06-30
- Accession: 0001558370-23-013763
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1133869/000155837023013763/capr-20230630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1133869/000155837023013763/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-04-01 to 2023-06-30 | $3.9m | us-gaap:Revenues |
| Revenue | 6 months, 2023-01-01 to 2023-06-30 | $6.9m | us-gaap:Revenues |
| Research and development | 3 months, 2023-04-01 to 2023-06-30 | $8.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2023-01-01 to 2023-06-30 | $16.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-04-01 to 2023-06-30 | −$7.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-01-01 to 2023-06-30 | −$15.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | −$7.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | −$15.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-04-01 to 2023-06-30 | −$0.29 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-01-01 to 2023-06-30 | −$0.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-04-01 to 2023-06-30 | −$0.29 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-01-01 to 2023-06-30 | −$0.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-04-01 to 2023-06-30 | 25,335,342 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-01-01 to 2023-06-30 | 25,291,591 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | −$5.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2023-01-01 to 2023-06-30 | $483.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-06-30 | $9.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-06-30 | $38.9m | us-gaap:AssetsCurrent |
| Total assets | at 2023-06-30 | $46.0m | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $35.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-06-30 | $43.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-06-30 | $2.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1133869/000155837023013763/capr-20230630x10q.htm

Filed Aug 8, 2023.
Source: SEC EDGAR, the filing index for accession 0001558370-23-013763. Last ingested by Listed: Nov 14, 2026, 18:39 ET. No prices; not investment advice.
